MarketResearchFuture.com adds “Liquid Biopsy Market – 2018 Global Analysis, Growth, Trends and Opportunities Research Report forecasting to 2022” reports to its database.
TRY FREE SAMPLE REPORT @ https://www.marketresearchfuture.com/sample_request/710 .
The global Liquid Biopsy market is currently valued at $ 3950 million and will reach $ 17,372.28 million growing at a CAGR of 28%.
The recent market developments has necessitated a ‘see through’ approach so as to avoid the slippery slope generated by the changing paradigms resulting from the powerful forces of economy, business models, competition and others. “Market Research future” presents its latest report titled “World Liquid Biopsy Market –forecast till 2022” to help clear the blur resulting from these developments and to give the reader a clear picture of the possibilities and nuisances lying ahead!
Depending on geographic region, Liquid biopsy market is segmented into four key regions: Americas, Europe, Asia Pacific, and Middle East & Africa. Globally developed countries led by North America is the largest market for Liquid biopsy. Europe is the second-largest market for liquid biopsy. The developing regions market such as Asia pacific region and Middle East & Africa however is rising much faster.
The report for Global Liquid Biopsy market of Market Research Future comprises extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.
Major Players of Global liquid biopsy market:
The major participants of this market are: Guardant Health, Inc., Trovagene, Inc., RainDance Technologies, Inc., Agena Bioscience Inc. Inc., Admera Health, Biocept, Inc., Circulogene Theranostics, Inivata Ltd., SAGA Diagnostics AB, Exosome Diagnostics and others.
Biopsy involves extracting a sample of tissue and testing it for the presence of diseases especially cancer. Traditional tissue biopsy is a painful technique and also has a high rate of false results. Moreover the technique is costly, time consuming and not applicable for extracting samples such as those close to vital organs such as heart. Liquid biopsy overcomes these problems of tissue biopsy by using biomarkers present in samples such as blood, urine etc. and thus is a comparatively non-invasive technique. Liquid biopsy also provides greater information about the sample which is real time. The real time data can be used for monitoring and thereby determining the treatment for diseases such as cancer. The greater sensitivity of tissue biopsy coupled with the development of sophisticated detectors with extremely low detection rates have enabled the early detection of diseases which is the holy grail of cancer.
Other market drivers for the liquid biopsy market are rising rates of cancer, growing investment in research and development, collaborations between companies and public organizations, rise in geriatric population, rising expenditure on health etc. The factors which are inhibiting the growth of the market includes the prohibitive costs associated with liquid biopsy and the differential awareness and availability between developing and the developed world. However, not all cancer patients benefit from early detection as some cancer types such as brain cancer and prostate cancer may lie dormant for many years. Further liquid biopsy is not all non-invasive as can be seen in case of using spinal fluid as sample.
Also the technique is not applicable to all types of cancer as some cancers such as brain cancer and prostate cancer may lie dormant for many years, and thus are either undetectable or detected very late which robs liquid biopsy of its advantages. Further liquid biopsy is not all non-invasive as can be seen in case of using spinal fluid as sample.
Global Liquid Biopsy Market has been segmented on the basis of biomarker type which comprises of circulating tumor cells (Ctcs), circulating tumor DNA (Ctdna), extracellular vesicles (Evs) and other biomarker. On the basis of application; market is segmented into cancer therapeutic application, reproductive health, and other therapeutic application. On the basis of sample; market is segmented into blood, urine and others. On the basis of end-users; market is segmented into hospitals and laboratories, academic and research centres and others.
CHAPTER 1. REPORT PROLOGUE
CHAPTER 2. INTRODUCTION
2.1 Scope Of Study
2.2 Research Objective
2.3 Assumptions & Limitations
2.4 Market Structure
CHAPTER 3. RESEARCH METHODOLOGY
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
CHAPTER 4. MARKET DYNAMICS
4.2.1 Comparatively Painless And Non-Invasive Technique
4.2.2 Early Real Time High Precision Detection Of Diseases
4.2.3 Useful For Designing Effective Treatment Strategies Based On The Real Time Molecular Assessment For The Progression Of The Disease
4.2.4 Rise In Cases Of Cancer And Other Diseases
4.2.5 Lifestyle Changes And Environmental Factors
4.2.6 Other Advantages Over Other Techniques
4.2.7 The Recent Technological Advancements Has Increased The Appeal Of Liquid Biopsy
4.2.8 Transferability Of Liquid Biopsy
4.2.9 Rising Investment In Research And Development And Collaborations Between Companies And Public Organizations
4.2.10 Greater Focus On Venture Capital
4.2.11 Demographical Factors
4.3.1 Prohibitive Costs Associated With Liquid Biopsy
4.3.2 Lower Sensitivity For Certain Biomarkers
4.3.3 Not All Cancers Patients Benefit From Early Detection
4.3.4 Liquid Biopsy Is Not All Non-Invasive
4.3.5 Differential Awareness And Availability Between Developing And Developed World
4.3.6 Issues In Venture Capital, Startups And Collaborations
4.4.1 Growing Collaboration Between Companies Has Become The Entrance Gateway For New Firms
4.4.2 Funding From Public Organizations Is A Good Strategy To Reduce Development Costs
4.4.3 Rise In Research And Development Investment
4.4.4 Developing Economies Provide An Unserved Market For Liquid Biopsy
4.4.5 Growing Trend Of Start-Ups And Venture Investment In The Field Of Liquid Biopsy
4.5.1 Information And Interest Gap Between The Investors And The Developers
4.5.2 Lack Of Trained Professionals In Developing Regions
4.5.3 Lack Of Standardization And Transparency
CHAPTER 5. MARKET FACTOR ANALYSIS
5.1 Porter’s Five Force Analysis
5.1.1 Bargaining Power Of Buyer
5.1.2 Bargaining Power Of Supplier
5.1.3 Threat From Substitute
5.1.4 Threat From A New Entrant
5.1.5 Intensity Of Competitive Rivalry
5.2 Value Chain Analysis
5.2.1 Device Manufacturers
5.2.2 Software Developers
5.2.3 Reagent And Accessory Suppliers
5.2.4 Healthcare Providers
AVAIL AMAZING DISCOUNT ON REPORT @ https://www.marketresearchfuture.com/check-discount/710 .
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
+1 646 845 9312